Literature DB >> 12955216

[Volumetric MRI for evaluation of regional pattern and progressin of neocortical degeneration in Alzheimer's disease].

G Leinsinger1, S Teipel, A Wismüller, C Born, T Meindl, W Flatz, S Schönberg, J Pruessner, H Hampel, M Reiser.   

Abstract

PURPOSE: Volumetric analysis of the corpus callosum and hippocampus using MRI in Alzheimer's disease (AD) to evaluate the regional pattern and progression of neocortical neurodegeneration.
METHODS: In subsequent studies we investigated patients with AD and healthy controls. Volumetry was based on MRI-data from a sagittal 3D T1w-gradient echo sequence. The corpus callosum (CC) was measured in a midsagittal slice, and subdivided into 5 subregions. Volumetry of the hippocampus/amygdala-formation (HAF) was performed by segmentation in coronary reoriented slices.
RESULTS: In AD patients we found a significant atrophy in the rostrum und splenium of CC. The atrophy was correlated with the severity of dementia, but no correlation was found with the load of white matter lesions. In comparison with (18)FDG-PET, we found a significant correlation of regional CC-atrophy with the regional decline of cortical glucose metabolism. A ROC-analysis demonstrated no significant differences in the diagnostic accuracy of HAF volumetry and regional CC volumetry of the splenium (region C5) even in mild stages of dementia.
CONCLUSION: Regional atrophy of CC can be used as a marker of neocortical degeneration even in early stages of dementia in AD.

Entities:  

Mesh:

Year:  2003        PMID: 12955216     DOI: 10.1007/s00117-003-0928-1

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  29 in total

1.  Corpus callosum measurement as an in vivo indicator for neocortical neuronal integrity, but not white matter pathology, in Alzheimer's disease.

Authors:  H Hampel; S J Teipel; G E Alexander; B Horwitz; P Pietrini; H Hippius; H J Möller; M B Schapiro; S I Rapoport
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

2.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.

Authors:  C R Jack; R C Petersen; Y C Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; S C Waring; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

3.  Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD.

Authors:  Y Xu; C R Jack; P C O'Brien; E Kokmen; G E Smith; R J Ivnik; B F Boeve; R G Tangalos; R C Petersen
Journal:  Neurology       Date:  2000-05-09       Impact factor: 9.910

Review 4.  Corpus callosum atrophy is a possible indicator of region- and cell type-specific neuronal degeneration in Alzheimer disease: a magnetic resonance imaging analysis.

Authors:  H Hampel; S J Teipel; G E Alexander; B Horwitz; D Teichberg; M B Schapiro; S I Rapoport
Journal:  Arch Neurol       Date:  1998-02

5.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

6.  Region-specific corpus callosum atrophy correlates with the regional pattern of cortical glucose metabolism in Alzheimer disease.

Authors:  S J Teipel; H Hampel; P Pietrini; G E Alexander; B Horwitz; E Daley; H J Möller; M B Schapiro; S I Rapoport
Journal:  Arch Neurol       Date:  1999-04

7.  Atrophy of the corpus callosum in Alzheimer's disease versus healthy aging.

Authors:  J S Janowsky; J A Kaye; R A Carper
Journal:  J Am Geriatr Soc       Date:  1996-07       Impact factor: 5.562

8.  Analysis of brain and cerebrospinal fluid volumes with MR imaging: impact on PET data correction for atrophy. Part II. Aging and Alzheimer dementia.

Authors:  N K Tanna; M I Kohn; D N Horwich; P R Jolles; R A Zimmerman; W M Alves; A Alavi
Journal:  Radiology       Date:  1991-01       Impact factor: 11.105

9.  In vivo imaging of region and cell type specific neocortical neurodegeneration in Alzheimer's disease. Perspectives of MRI derived corpus callosum measurement for mapping disease progression and effects of therapy. Evidence from studies with MRI, EEG and PET.

Authors:  H Hampel; S J Teipel; G E Alexander; O Pogarell; S I Rapoport; H-J Möller
Journal:  J Neural Transm (Vienna)       Date:  2002-05       Impact factor: 3.575

10.  Quantitative NMR measurements of hippocampal atrophy in Alzheimer's disease.

Authors:  J P Seab; W J Jagust; S T Wong; M S Roos; B R Reed; T F Budinger
Journal:  Magn Reson Med       Date:  1988-10       Impact factor: 4.668

View more
  2 in total

1.  Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database.

Authors:  Sean M Nestor; Raul Rupsingh; Michael Borrie; Matthew Smith; Vittorio Accomazzi; Jennie L Wells; Jennifer Fogarty; Robert Bartha
Journal:  Brain       Date:  2008-07-11       Impact factor: 13.501

2.  Dementia in Down's syndrome: an MRI comparison with Alzheimer's disease in the general population.

Authors:  Diane Mullins; Eileen Daly; Andrew Simmons; Felix Beacher; Catherine Ml Foy; Simon Lovestone; Brian Hallahan; Kieran C Murphy; Declan G Murphy
Journal:  J Neurodev Disord       Date:  2013-08-20       Impact factor: 4.025

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.